AccuraGen Raises $40M in Series B Financing
June 1, 2016

NEW YORK (GenomeWeb) – Liquid biopsy startup AccuraGen said today that it has raised $40 million in a Series B financing round to support development and commercialization of its liquid biopsy technology, dubbed Firefly.

Junson Capital, Decheng Capital, Temasek investments, DT Capital, Stanford-StartX Fund, and Nan Fung Capital, along with Series A investors, participated in the round.

In addition, the company said that it had appointed Dan Zabrowski, head of sequencing and tissue diagnostics at Roche, and Junson Capital CEO Kevin Liu to its board.

AccuraGen, which has a 20-member team headquartered in Menlo Park, California and also has a 45-member clinical team in Shanghai, described its technology earlier this year at the Molecular Medicine Tri-Conference in San Francisco. AccuraGen said then that it was developing a 61-gene NGS-based test to analyzing circulating tumor DNA and conducting clinical research studies with collaborators in China.

Last year, the company raised $6.9 million in a Series A round led by Decheng Capital and Denlux Capital, along with Yifang Group Holdings Limited and WS Investment.

Copyright ? 2011 Decheng Capital LLC. All Rights Reserved.
浙江20选5预测推荐 河内五分彩走势图彩经网 四场进球彩 世界杯比分吧 mg电子特大奖视频 昂热vs日尔曼历史交战 MG水果大战-官方 快乐12前三直遗漏数据 河北福利彩票双色球 快乐888 今日四川快乐12开奖结果 股票走势图怎么看 qq武汉麻将刷分 坐标图网 重庆时时彩官网结果 2021新版跑狗图 今论坛 吉林11选5历史开奖